New Mouth-Dissolving treatment tested for aggressive brain cancer recurrence

NCT ID NCT06011109

First seen Nov 01, 2025 · Last updated Apr 06, 2026 · Updated 30 times

Summary

This study is testing whether adding a new experimental medicine called APG-157, taken as dissolving pastilles in the mouth, can improve outcomes for people whose high-grade glioma (a type of aggressive brain tumor) has returned after previous treatment. Participants will take the APG-157 pastilles three times daily while continuing their standard bevacizumab infusions. The main goals are to see if this combination helps slow tumor growth, extends life, and improves quality of life for up to 30 adults with this condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.